<DOC>
	<DOCNO>NCT00198393</DOCNO>
	<brief_summary>Patients present deterioration general state ( performance status [ PS ] 2-3 ) , constitute population need adapt treatment . An analysis make evolution PS 2 patient include Eastern Cooperative Oncology Group ( ECOG ) 1594 trial evaluate association new cytotoxic agent ( gemcitabine , paclitaxel , docetaxel ) cisplatin . During trial , inclusion patient stop due occurrence toxicity frequent population ( PS 0-1 ) . At end study , analysis total toxicity , one high note group PS 0 1 patient . In population PS 2 patient , 5 death note , analysis show 2 due treatment . It note low survival compare others related disease treatment . These patient often symptomatic need palliative treatment . The benefit chemotherapy deny . They profit monochemotherapy new cytotoxic agent , without associate platinum salt .</brief_summary>
	<brief_title>Randomized Phase 2 Study 3 Therapeutic Modalities PS 2/3 Patients With NSCLC Stage IIIB/IV</brief_title>
	<detailed_description>Arm A Iressa 250 mg daily PROG/TOX -- &gt; Taxotere 75 mg/m² d1 ( d1=d22 ) Arm B Gemzar 1250 mg/m² d1 &amp; d8 ( d1=d22 ) PROG/TOX -- &gt; Iressa 250 mg daily Arm C Taxotere 75 mg/m² d1 ( d1=d22 ) PROG/TOX -- &gt; Iressa 250 mg daily</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Stage IIIB/IV NSCLC patient performance status 2 3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>stage IIIB/IV NSCLC</keyword>
	<keyword>patient performance status 2 3 .</keyword>
</DOC>